Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 457 of 5804
-
New vaccine shows promise against Traveler's diarrhea in early trial
⭐️ VACCINE ⭐️ CompletedThe study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:09 UTC
-
Immunotherapy plus chemo before surgery: a new hope for breast cancer?
Disease control Recruiting nowA Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Stroke recovery breakthrough? new study tests simple blood flow trick
Disease control Recruiting nowAcute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therap…
Phase: NA • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for advanced cervical cancer: drug trial targets remaining risk
Disease control OngoingThis is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could olive juice compounds help shield the aging brain?
Prevention Recruiting nowNutrition is an important modifiable risk factor of human cognitive health. Increasing data suggests that certain nutrients or food ingredients, such as plant polyphenols, have the potential to benefit cognitive abilities even in later life. In terms of polyphenols, Hydroxytyroso…
Phase: NA • Sponsor: Panhellenic Federation of Alzheimer's Disease and Related Disorders • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New hope for lung cancer: drug cocktail trial launches
Disease control Recruiting nowResearchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chem…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control Recruiting nowThis study targets patients with advanced NSCLC driven with positive driver genes who have failed TKI treatment, enrolling 66-78 participants. Cohort1 :Patients will receive JS207 (10 or 15 mg/kg, IV, d1) + pemetrexed (500 mg/m², IV, d1) + platinum-based chemotherapy (carboplatin…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot could shield against malaria for months
Prevention CompletedThis study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common. Part A is an open-label study conducted in healthy adults whereas P…
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
New asthma drug could cut attacks for patients not helped by standard inhalers
Disease control Recruiting nowThis study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New dosing strategy aims to keep myeloma patients out of the hospital
Disease control Recruiting nowA phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to imp…
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in shrinking cervical tumors before surgery
Disease control OngoingThe goal of this clinical trial is to determine the effectiveness of the combination therapy of Eparbrutinib (QL1706) with neoadjuvant chemotherapy followed by Type I hysterectomy in treating locally advanced cervical cancer. Additionally, it will assess the safety profile of thi…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Squeeze away hypertension? handgrip device put to the test
Disease control Recruiting nowThe study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not curre…
Phase: NA • Sponsor: Zona Health, Inc • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New model aims to eliminate HIV transmission from mothers to infants in malawi
Prevention Recruiting nowPurpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to: 1. Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing. 2. Estimate the effect of the PAC-Man model, compared to SOC, on the propo…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo before surgery aims to control advanced lung cancer
Disease control Recruiting nowA Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).
Phase: PHASE2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug duo aims to shrink lung tumors in First-Line trial
Disease control TerminatedThe study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Leukemia transplant study tests lower radiation for better outcomes
Disease control Recruiting nowThis is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to comp…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New TB vaccine candidate MTBVAC enters Mid-Stage human trial
⭐️ VACCINE ⭐️ OngoingPhase II trial to establish the safety, reactogenicity, and immunogenicity of the MTBVAC with a licensed BCG vaccine as a comparator in both TB naïve (QFT PLUS negative) and TB exposed (QFT PLUS positive) healthy adults and adolescents.
Phase: PHASE2 • Sponsor: Bharat Biotech International Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:25 UTC